Stock events for Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics experienced several stock-impacting events in the past six months. The company's Q4 and full-year 2025 financial results showed a decrease in collaboration revenue and a net loss due to the completion of work under the VX-670 collaboration research plan and increased R&D spending. A positive recommendation from the DMC allowed for the initiation of Cohort 2 in the ELEVATE-44-201 study for DMD. Analysts have given Entrada Therapeutics a consensus rating of "Moderate Buy" with an average 1-year target price of $18.50. The company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) in March 2026.
Demand Seasonality affecting Entrada Therapeutics, Inc.’s stock price
As a clinical-stage biopharmaceutical company without commercial products, Entrada Therapeutics, Inc. does not have information available regarding demand seasonality. The company's revenue primarily comes from collaboration agreements, which are not typically subject to seasonal fluctuations.
Overview of Entrada Therapeutics, Inc.’s business
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for intracellular targets using its EEV™ platform. The company targets rare and serious diseases, including Duchenne Muscular Dystrophy (DMD) with programs like ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51, Myotonic Dystrophy Type 1 (DM1) in partnership with Vertex Pharmaceuticals for VX-670, Lysosomal Storage Diseases (LSDs) with EN401 and EN301, and Usher syndrome type 2A (USH2A) with ENTR-801.
TRDA’s Geographic footprint
Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States. The company aims to serve patients globally by pursuing regulatory filings in key markets and collaborating with academic partners and contract development organizations.
TRDA Corporate Image Assessment
Entrada Therapeutics has maintained a generally favorable reputation, reflected by a "Moderate Buy" consensus rating from analysts. Positive clinical updates and a strong cash position have helped mitigate concerns from a decline in collaboration revenue and a shift to a net loss in 2025. No specific events have severely damaged the company's brand reputation in the past year.
Ownership
Entrada Therapeutics, Inc. has significant institutional ownership, with approximately 86.39% of the stock held by institutions such as Baker Bros. Advisors Lp, BlackRock, Inc., and Vanguard Group Inc. Insider ownership stands at approximately 8.11%, with Felix Baker owning the most shares among individual investors, while retail investors hold around 46.46% of the stock.
